

TRADEMARK ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Biosite Incorporated		06/29/2007	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	General Electric Capital Corporation, as Agent
Street Address:	2 Bethesda Metro Center, Suite 600
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20814
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 15

Property Type	Number	Word Mark
Serial Number:	78574678	MULTI MARKER INDEX
Registration Number:	2453707	AN UNFAIR ADVANTAGE
Serial Number:	75609841	OMNICLONAL
Serial Number:	78056518	IN TIME TO DECIDE
Serial Number:	78072981	NEW DIMENSIONS IN DIAGNOSIS
Serial Number:	74489582	ASCEND MULTIMUNOASSAY
Serial Number:	74260208	BIOSITE
Serial Number:	74260475	BIOSITE
Serial Number:	76634473	BIOSITE
Serial Number:	74525008	TRIAGE
Serial Number:	75172105	TPP
Serial Number:	75075619	EXPRESS TEST
Serial Number:	75099733	EXPRESS TEST
Serial Number:	78178159	CARDIO PROFILER

OP \$390.00 78574678

900081174

TRADEMARK
REEL: 003575 FRAME: 0626

Serial Number:

75655110

BIOSITE DISCOVERY AN UNFAIR ADVANTAGE

CORRESPONDENCE DATA

Fax Number: (212)230-7735

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 212-318-6535

Email: traceybennett@paulhastings.com

Correspondent Name: Tracey D. Bennett

Address Line 1: Paul, Hastings

Address Line 2: 75 E. 55th Street

Address Line 4: New York, NEW YORK 10022

NAME OF SUBMITTER:	Tracey D. Bennett
Signature:	/s/Tracey D. Bennett
Date:	07/06/2007

Total Attachments: 47

source=Second Lien IP Security Agreement#page1.tif
source=Second Lien IP Security Agreement#page2.tif
source=Second Lien IP Security Agreement#page3.tif
source=Second Lien IP Security Agreement#page4.tif
source=Second Lien IP Security Agreement#page5.tif
source=Second Lien IP Security Agreement#page6.tif
source=Second Lien IP Security Agreement#page7.tif
source=Second Lien IP Security Agreement#page8.tif
source=Second Lien IP Security Agreement#page9.tif
source=Second Lien IP Security Agreement#page10.tif
source=Second Lien IP Security Agreement#page11.tif
source=Second Lien IP Security Agreement#page12.tif
source=Second Lien IP Security Agreement#page13.tif
source=Second Lien IP Security Agreement#page14.tif
source=Second Lien IP Security Agreement#page15.tif
source=Second Lien IP Security Agreement#page16.tif
source=Second Lien IP Security Agreement#page17.tif
source=Second Lien IP Security Agreement#page18.tif
source=Second Lien IP Security Agreement#page19.tif
source=Second Lien IP Security Agreement#page20.tif
source=Second Lien IP Security Agreement#page21.tif
source=Second Lien IP Security Agreement#page22.tif
source=Second Lien IP Security Agreement#page23.tif
source=Second Lien IP Security Agreement#page24.tif
source=Second Lien IP Security Agreement#page25.tif
source=Second Lien IP Security Agreement#page26.tif
source=Second Lien IP Security Agreement#page27.tif
source=Second Lien IP Security Agreement#page28.tif
source=Second Lien IP Security Agreement#page29.tif
source=Second Lien IP Security Agreement#page30.tif
source=Second Lien IP Security Agreement#page31.tif
source=Second Lien IP Security Agreement#page32.tif

source=Second Lien IP Security Agreement#page33.tif
source=Second Lien IP Security Agreement#page34.tif
source=Second Lien IP Security Agreement#page35.tif
source=Second Lien IP Security Agreement#page36.tif
source=Second Lien IP Security Agreement#page37.tif
source=Second Lien IP Security Agreement#page38.tif
source=Second Lien IP Security Agreement#page39.tif
source=Second Lien IP Security Agreement#page40.tif
source=Second Lien IP Security Agreement#page41.tif
source=Second Lien IP Security Agreement#page42.tif
source=Second Lien IP Security Agreement#page43.tif
source=Second Lien IP Security Agreement#page44.tif
source=Second Lien IP Security Agreement#page45.tif
source=Second Lien IP Security Agreement#page46.tif
source=Second Lien IP Security Agreement#page47.tif

SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of June 26, 2007, is made by each of the entities listed on the signature pages hereof (each a "Grantor" and, collectively, the "Grantors"), in favor of General Electric Capital Corporation ("GE Capital"), as administrative agent and collateral agent (in such capacity, together with its successors and permitted assigns, the "Administrative Agent") for the Lenders and the L/C Issuers (as defined in the Second Lien Credit Agreement referred to below).

W I T N E S S E T H:

WHEREAS, pursuant to the Second Lien Credit Agreement, dated as of June 26, 2007 (as amended, restated, supplemented or otherwise modified from time to time, the "Second Lien Credit Agreement"), among the Borrower, Holdings and the Lenders from time to time party thereto and Administrative Agent and the Lenders have severally agreed to make extensions of credit to the Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, each Grantor has agreed, pursuant to a Second Lien Guaranty and Security Agreement of dated as of June 26, 2007 herewith in favor of the Administrative Agent (the "Guaranty and Security Agreement"), to guarantee the Obligations (as defined in the Second Lien Credit Agreement) of the other Loan Parties; and

WHEREAS, all of the Grantors are party to the Guaranty and Security Agreement pursuant to which the Grantors are required to execute and deliver this Intellectual Property Security Agreement.

NOW, THEREFORE, in consideration of the premises and to induce the Lenders and the Administrative Agent to enter into the Second Lien Credit Agreement and to induce the Lenders to make or continue to make their respective extensions of credit to the Borrower thereunder, each Grantor hereby agrees with the Administrative Agent as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

Section 2. Grant of Security Interest in Intellectual Property Collateral. Each Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations on the terms set forth in the Loan Documents, hereby mortgages, pledges and hypothecates to the Administrative Agent, for the benefit of the Secured Parties, and grants to the Administrative Agent, for the benefit of the Secured Parties, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of such Grantor (the "Intellectual Property Collateral"):

(a) Copyrights.

(i) all of its Copyrights and registrations and applications for registration thereof and all registered IP Licenses and applications therefor providing for the grant to such Grantor of any right under any Copyright, including, without limitation, those referred to on Schedule 1A hereto;

- (ii) all renewals, reversions and extensions of the foregoing;
- (iii) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

(b) Patents.

(i) all of its registered Patents and applications for registration therefor and all registered IP Licenses and applications thereof providing for the grant to such Grantor of any right under any Patent, including, without limitation, those referred to on Schedule 1B hereto;

(ii) all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(iii) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

(c) Trademarks.

(i) all of its Trademarks and applications for registration thereof and all registered IP Licenses and applications therefor providing for the grant to such Grantor of any right under any Trademark, including, without limitation, those referred to on Schedule 1C hereto;

(ii) all renewals and extensions of the foregoing;

(iii) all goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

(iv) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

Section 3. Guaranty and Security Agreement. The security interest granted pursuant to this Intellectual Property Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Guaranty and Security Agreement and each Grantor hereby acknowledges and agrees that the rights and remedies of the Administrative Agent with respect to the security interest in the Intellectual Property Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantor Remains Liable. Each Grantor hereby agrees that, anything herein to the contrary notwithstanding, such Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with such Grantor's Intellectual Property Collateral and IP Licenses subject to a security interest hereunder.

Section 5. Counterparts. This Intellectual Property Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.

Section 6. Governing Law. This Intellectual Property Security Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.


[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, each Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

IM US HOLDINGS, LLC
INVERNESS MEDICAL INNOVATIONS, INC.
ADVANTAGE DIAGNOSTICS CORPORATION
APPLIED BIOTECH, INC.
BINAX, INC.
FIRST CHECK DIAGNOSTICS CORP.
FOREFRONT DIAGNOSTICS, INC.
INCA ACQUISITION, INC.
INNOVATIVE MOBILITY, LLC
INSTANT TECHNOLOGIES, INC.
INVERNESS MEDICAL – BIOSTAR, INC.
INVERNESS MEDICAL INTERNATIONAL HOLDING CORP.
INVERNESS MEDICAL INTERNATIONAL HOLDING CORP. II
INNOVATIONS RESEARCH, LLC
INVERNESS MEDICAL, LLC
ISCHEMIA TECHNOLOGIES, INC.
IVC INDUSTRIES, INC.
INNOVACON, INC.
OSTEX INTERNATIONAL, INC.
QUALITY ASSURED SERVICES, INC.
SELF CARE TECHNOLOGY, INC.
SPDH, INC.
UNIPATH ONLINE, INC.
WAMPOLE LABORATORIES, LLC, as Grantors

Approved
As To Form



Legal Department

By: 
Name: David Teitel

Title: President, Chief Financial Officer & Treasurer,
Vice President, Finance, Vice President, Vice
President, Finance, Vice President, Finance,
Vice President, Treasurer, Chief Financial
Officer, Vice President, Finance, Vice President,
Finance, President, President, Vice
President, Finance, Vice President, Finance,
Vice President, Finance, Vice President,
Finance, Vice President, Finance, Vice
President, Finance, Chief Financial Officer, Vice
President, Finance, President, Vice
President, Vice President

ACCEPTED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION,
as Administrative Agent

By: 

Name:

Title:

Andrew D Moore
Duly Authorized Signatory

[SIGNATURE PAGE TO SECOND LIEN IP SECURITY AGREEMENT]

LEGAL_US_B # 75504436

TRADEMARK
REEL: 003575 FRAME: 0633

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

A. REGISTERED COPYRIGHTS

None.

B. COPYRIGHT APPLICATIONS

None.

C. REGISTERED IP LICENSES AND ANY APPLICATIONS THEREFOR

None.

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

A. REGISTERED PATENTS

[Include Owner, Registration Number and Date]

B. PATENT APPLICATIONS

[Include Owner, Application Number and Date]

C. REGISTERED IP LICENSES AND ANY APPLICATIONS THEREFOR

[Include complete legal description of agreement (name of agreement, parties and date)]

File Number	Country	Filing date	Filing number	Grant date	Grant number	List of Owners or Assignees
IM0089	AT	19/MAR/2004	GW905/2004	10/APR/2006	16422	Advantage Diagnostics Corporation
IM0089	AU	19/MAR/2004	200445458	06/APR/2006	212004000325	Advantage Diagnostics Corporation
IM0089	BR	19/MAR/2004	P10411058.5	13/APR/2007	DK200500290	Advantage Diagnostics Corporation
IM0089	CA	19/MAR/2004	2528108			Advantage Diagnostics Corporation
IM0089	CN	19/MAR/2004	20048015772.7			Advantage Diagnostics Corporation
IM0089	CZ	19/MAR/2004	20063402032.5			Advantage Diagnostics Corporation
IM0089	DE	19/MAR/2004	B126340290			Advantage Diagnostics Corporation
IM0089	DK	19/MAR/2004	04785762.8			Advantage Diagnostics Corporation
IM0089	EP	19/MAR/2004	08106552.1			Advantage Diagnostics Corporation
IM0089	HK	19/MAR/2004	2006-509248			Advantage Diagnostics Corporation
IM0089	JP	19/MAR/2004	20-2405-7004007			Advantage Diagnostics Corporation
IM0089	KR	19/MAR/2004	PAJU2005/000363			Advantage Diagnostics Corporation
IM0089	MX	19/MAR/2004	2005003732			Advantage Diagnostics Corporation
IM0089	PT	19/MAR/2004	2005138919	27/NOV/2006	5817	Advantage Diagnostics Corporation
IM0089	RU	19/MAR/2004	200512159/M	15/JAN/2007	19871	Advantage Diagnostics Corporation
IM0089	UA	19/MAR/2004	200512159/M			Advantage Diagnostics Corporation
IM0089	US	06/JUN/2003	10/455771	22/AUG/2000	6106732	Applied Biotech, Inc.
AB10005	CA	23/JUL/2002	2455404	15/APR/2003	6548309	Applied Biotech, Inc.
IM0079	US	02/JUN/2003	09/10453117	30/JAN/2003	759833	Binax, Inc.
BNX0001	US	16/APR/1998	09/044577	17/OCT/2006	2342141	Binax, Inc.
BNX0002	US	19/MAR/1998	09/044577	28/JAN/2004	99810035.8	Binax, Inc.
BNX0002	AU	25/AUG/1999	569323199	03/JAN/2007	1107773	Binax, Inc.
BNX0003	CA	25/AUG/1999	2342141			Binax, Inc.
BNX0003	CN	25/AUG/1999	99810035.8			Binax, Inc.
BNX0003	EP	25/AUG/1999	99843941.7			Binax, Inc.
BNX0003	JP	25/AUG/1999	2000-565904			Binax, Inc.
BNX0003	MX	25/AUG/1999	PAJU2001/002057	03/APR/2007	244714	Binax, Inc.
BNX0003	US	25/AUG/1999	09/1132720			Binax, Inc.
BNX0003	AT	20/SEP/1999	99948305.0	20/APR/2006	E293457	Binax, Inc.
BNX0004	AU	20/SEP/1999	61513199	24/JUL/2003	759529	Binax, Inc.
BNX0004	BE	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	CA	20/SEP/1999	2342783	20/APR/2005	1113817	Binax, Inc.
BNX0004	CH	20/SEP/1999	99948305.0	17/AUG/2005	99811042.6	Binax, Inc.
BNX0004	CN	20/SEP/1999	99811042.6	20/APR/2005	1113817	Binax, Inc.
BNX0004	DE	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	DK	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	EP	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	ES	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	FI	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	FR	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	GB	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	IE	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	IT	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	JP	20/SEP/1999	2000-573764	17/NOV/2005	232213	Binax, Inc.
BNX0004	MX	20/SEP/1999	PAJU2001/002822	20/APR/2005	1113817	Binax, Inc.
BNX0004	NL	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	PT	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.

BNX0004	SE	20/SEP/1999	99948305.0	20/APR/2005	1113817	Binax, Inc.
BNX0004	US	16/SEP/1999	09/397110	30/NOV/2004	6824997	Binax, Inc.
BNX0005	US	19/NOV/1999	09443211	27/APR/2004	6727073	Binax, Inc.
BNX0006	AU	11/DEC/2000	24285/01	16/MAR/2006	783777	Binax, Inc.
BNX0006	CA	11/DEC/2000	2393628	Binax, Inc.	11/DEC/2020	11/DEC/2020
BNX0006	EP	11/DEC/2000	0988037.8	Binax, Inc.	10/DEC/2019	10/DEC/2019
BNX0006	US	10/DEC/1999	0945898	01/SEP/2005	2001241867	01/MAR/2021
BNX0007	AU	01/MAR/2001	2001241867	01/AUG/2002	2427693	19/AUG/2022
BNX0007	CA	19/AUG/2002	2427693	Binax, Inc.	01/MAR/2021	01/MAR/2021
BNX0007	EP	01/MAR/2001	01913177.0	Binax, Inc.	01/MAR/2021	01/MAR/2020
BNX0007	JP	01/MAR/2001	2001-563134	Binax, Inc.	15/JAN/2022	15/JAN/2022
BNX0007	US	01/MAR/2000	09/518165	Binax, Inc.	27/FEB/2022	27/FEB/2022
BNX0008	US	15/JAN/2002	10/04920	07/FEB/2005	11/295486	24/FEB/2024
BNX0008	US	07/DEC/2005	10/04920	27/FEB/2002	10/083476	24/FEB/2024
BNX0009	US	27/FEB/2002	10/083476	24/FEB/2004	2004216189	24/FEB/2024
BNX0011	AU	24/FEB/2004	2004216189	24/FEB/2004	2516546	24/FEB/2024
BNX0011	CA	24/FEB/2004	2516546	24/FEB/2004	200480006045.4	24/FEB/2024
BNX0011	CN	24/FEB/2004	200480006045.4	24/FEB/2004	04714110.6	24/FEB/2024
BNX0011	EP	24/FEB/2004	04714110.6	24/FEB/2004	0610586.0	24/FEB/2024
BNX0011	HK	24/FEB/2004	0610586.0	24/FEB/2004	2006-503810	24/FEB/2024
BNX0011	JP	24/FEB/2004	2006-503810	24/APR/2004	10/784155	24/FEB/2024
BNX0011	US	24/APR/2004	10/784155	29/JUL/2005	200510084709.5	29/JUL/2025
BNX0012	CN	29/JUL/2005	200510084709.5	16/NOV/2004	10/949050	16/SEP/2019
BNX0012	US	16/NOV/2004	10/949050	23/MAY/2007	11/1740733	08/DEC/2007
BNX0012	US	23/MAY/2007	11/1740733	08/DEC/2006	60/673865	08/AUG/2007
BNX0015	US	08/DEC/2006	60/673865	08/AUG/2006	60/636200	01/MAR/2007
BNX0016	US	08/AUG/2006	60/636200	01/MAR/2005	200580013856.1	01/MAR/2025
BNX0016	CN	01/MAR/2005	200580013856.1	01/MAR/2005	05724003.8	26/NOV/2023
BNX0018	EP	01/MAR/2005	05724003.8	26/NOV/2003	2003295951	26/NOV/2023
BNX0018	IN	26/NOV/2003	2003295951	26/NOV/2003	2541135	26/NOV/2023
BNX0019	AU	26/NOV/2003	2541135	26/NOV/2003	200380110715.2	26/NOV/2023
BNX0019	CA	26/NOV/2003	200380110715.2	26/NOV/2003	03787166.2	26/NOV/2023
BNX0019	CN	26/NOV/2003	03787166.2	26/NOV/2003	17861/KOLNP/2006	26/NOV/2023
BNX0019	EP	26/NOV/2003	17861/KOLNP/2006	26/NOV/2003	2005-512837	26/NOV/2023
BNX0019	JP	26/NOV/2003	2005-512837	26/NOV/2003	PCT/US2003/037787	26/NOV/2023
BNX0019	NZ	26/NOV/2003	PCT/US2003/037787	16/NOV/2004	10/983973	26/NOV/2023
BNX0019	US	16/NOV/2004	10/983973	17/FEB/2005	20058000958.1	17/FEB/2025
BNX0019	CN	17/FEB/2005	20058000958.1	17/FEB/2005	05723144.1	17/FEB/2025
BNX0020	EP	17/FEB/2005	05723144.1	17/FEB/2005	PCT/US2005/004896	17/FEB/2025
BNX0020	IN	17/FEB/2005	PCT/US2005/004896	17/FEB/2005	2006-554175	17/FEB/2024
BNX0020	JP	17/FEB/2005	2006-554175	17/FEB/2005	11/060113	17/FEB/2024
BNX0020	US	17/FEB/2005	11/060113	17/FEB/2005	11/060113	17/FEB/2025
BNX0021	CN	17/FEB/2005	11/060113	06/OCT/2005	PCT/US2005/035967	06/OCT/2025
BNX0021	EP	06/OCT/2005	PCT/US2005/035967	BNX0022	CN	

BNX0022	EP	06/OCT/2005	PCTTUS2005/035967	Binax, Inc.
BNX0022	IN	06/OCT/2005	PCTTUS2005/035967	Binax, Inc.
BNX0022	JP	06/OCT/2005	11/244986	Binax, Inc.
BNX0022	US	06/OCT/2005	PCTTUS2005/035967	Binax, Inc.
BNX0026	US	08/DEC/2008	60/873741	Binax, Inc.
BNX0027	US	05/JAN/2007	60/678750	Binax, Inc.
BNX0028	US	20/OCT/2006	60/1553264	Binax, Inc.
BNX0029	US	17/JAN/2007	60/880731	Binax, Inc.
BNX0033	US	10/APR/2007	60/910904	Binax, Inc.
BNX0023	US	02/SEP/2003	10/653321	Frontfront Diagnostics, Inc.
AB0006	CA	22/MAY/2001	24/09151	Inverness Medical - Biostar Inc.
AB0007	CA	29/MAR/2002	24/43077	Inverness Medical - Biostar Inc.
BST0001	AU	07/DEC/2000	20750701	Inverness Medical - Biostar Inc.
BST0001	CN	07/DEC/2000	008170037	Inverness Medical - Biostar Inc.
BST0001	DE	07/DEC/2000	009840711	Inverness Medical - Biostar Inc.
BST0001	EP	07/DEC/2000	009840711	Inverness Medical - Biostar Inc.
BST0001	FR	07/DEC/2000	009840711	Inverness Medical - Biostar Inc.
BST0001	GB	07/DEC/2000	009840711	Inverness Medical - Biostar Inc.
BST0001	JP	07/DEC/2000	2001-54519	Inverness Medical - Biostar Inc.
BST0001	KR	07/DEC/2000	2002-7007547	Inverness Medical - Biostar Inc.
BST0001	TW	07/MAR/2001	89126738	Inverness Medical - Biostar Inc.
BST0001	US	14/DEC/2000	09/737635	Inverness Medical - Biostar Inc.
BST0001	US	15/APR/2002	10/123750	Inverness Medical - Biostar Inc.
BST0002	TW	09/JAN/2001	89115794	NI-144899
BST0004	DE	20/MAR/1991	91910056.0	18/SEP/1986 69122252.5
BST0004	EP	20/MAR/1991	91910056.0	18/SEP/1986 0539383
BST0004	ES	20/MAR/1991	91910056.0	18/SEP/1986 0539383
BST0004	FR	20/MAR/1991	91910056.0	18/SEP/1986 0539383
BST0004	GB	20/MAR/1991	91910056.0	18/SEP/1986 0539383
BST0004	HK	20/MAR/1991	97102308.7	24/APR/1998 1000735
BST0004	IT	20/MAR/1991	91910056.0	18/SEP/1996 0539383
BST0004	JP	20/MAR/1991	509344/91	25/MAY/2001 3153373
BST0005	DE	18/SEP/1990	90914615.1	26/FEB/1987 69030004.2
BST0005	EP	18/SEP/1990	90914615.1	26/FEB/1987 0493484
BST0005	FR	18/SEP/1990	90914615.1	26/FEB/1987 0493484
BST0005	GB	18/SEP/1990	90914615.1	26/FEB/1987 0493484
BST0005	HK	18/SEP/1990	97102316.7	24/APR/1998 1000736
BST0005	IT	18/SEP/1990	90914615.1	26/FEB/1987 0493484
BST0005	JP	18/SEP/1990	2-513789	21/AUG/1998 2818292
BST0005	JP	18/SEP/1990	10-5911	26/FEB/1997 0493484
BST0005	US	31/JUL/1992	07923304	21/NOV/1995 5463606
BST0005	US	28/MAR/1995	08/141260	24/APR/1998 1000736
BST0005	US	11/FEB/1992	92906298.0	17/JUN/1997 5639671
BST0006	DE	11/FEB/1992	92906298.0	24/JUL/2002 0524301
BST0006	EP	11/FEB/1992	92906298.0	24/JUL/2002 0524301
BST0006	ES	11/FEB/1992	92906298.0	24/JUL/2002 0524301
BST0006	FR	11/FEB/1992	92906298.0	24/JUL/2002 0524301
BST0006	GB	11/FEB/1992	92906298.0	24/JUL/2002 0524301
BST0006	HK	11/FEB/1992	98100895.9	21/MAR/2003 1001889

BST0006	IT	JP	JP	11/FEB/1992	92906299.0	24/JUL/2002	0524301
BST0006	JP	JP	JP	11/FEB/1992	505739/92	28/JUL/2006	3833507
BST0006	US	US	US	16/SEP/2003	2001-312846	27/AUG/1996	5550063
BST0006	DE	DE	DE	10/JUN/1993	08/076347	25/NOV/1988	69227655.6
BST0007	EP	EP	EP	11/FEB/1992	92907304.7	25/NOV/1988	0525178
BST0007	ES	ES	ES	11/FEB/1992	92907304.7	25/NOV/1988	0525178
BST0007	FR	FR	FR	11/FEB/1992	92907304.7	25/NOV/1988	0525178
BST0007	GB	GB	GB	11/FEB/1992	92907304.7	25/NOV/1988	0525178
BST0007	HK	HK	HK	11/FEB/1992	98100899.5	24/MAR/2000	1001890
BST0007	IT	IT	IT	11/FEB/1992	92907304.7	25/NOV/1988	0525178
BST0008	BE	BE	BE	01/OCT/1991	911308968.6	10/SEP/1997	0546222
BST0008	DE	DE	DE	01/OCT/1991	911308968.6	10/SEP/1997	0546222
BST0008	EP	EP	EP	01/OCT/1991	911308968.6	10/SEP/1997	0546222
BST0008	ES	ES	ES	01/OCT/1991	911308968.6	10/SEP/1997	0546222
BST0008	FR	FR	FR	01/OCT/1991	911308968.6	10/SEP/1997	0546222
BST0008	GB	GB	GB	01/OCT/1991	911308968.6	10/SEP/1997	0546222
BST0008	HK	HK	HK	01/OCT/1991	97102305.6	24/APR/1998	1000771
BST0008	JP	JP	JP	24/SEP/1992	198609/98	08/SEP/2000	3107787
BST0008	JP	JP	JP	24/SEP/1992	254562/92	02/OCT/1998	2824950
BST0009	US	US	US	10/JUN/1993	08/076320	09/JAN/1996	5482830
BST0009	US	US	US	17/APR/1995	08/413565	21/SEP/1999	5935377
BST0009	US	US	US	31/MAY/1995	08/436040	13/MAY/1997	5629214
BST0009	US	US	US	31/MAY/1995	08/455652	09/SEP/1999	5889272
BST0010	EP	EP	EP	10/JUN/1993	08/076719	23/MAY/1995	54/18136
BST0011	HK	HK	HK	10/JUN/1993	01108521.4	23/MAY/2007	1126278
BST0011	EP	EP	EP	10/JUN/1993	93815341.7	14/DEC/2005	0727038
BST0011	EP	EP	EP	10/JUN/1993	05027236.8	14/DEC/2005	0727038
BST0011	GB	GB	GB	10/JUN/1993	93915341.7	23/MAY/2007	1126278
BST0011	GB	GB	GB	10/JUN/1993	01108521.4	13/OCT/2006	1003304
BST0011	HK	HK	HK	10/JUN/1993	98102356.0	20/MAY/1997	5631171
BST0011	JP	JP	JP	10/JUN/1993	2001-236593	28/APR/2005	3673489
BST0011	JP	JP	JP	10/JUN/1993	2001-236166	01/AUG/2003	3456984
BST0011	JP	JP	JP	10/JUN/1993	2001-236411	26/DEC/2003	3506703
BST0011	JP	JP	JP	10/JUN/1993	1984-505280	31/MAR/2006	3787143
BST0011	JP	JP	JP	10/JUN/1993	276589/2004	23/APR/2004	3547723
BST0011	JP	JP	JP	03/AUG/2001	2001-236198	26/DEC/2003	3507048
BST0011	JP	JP	JP	03/AUG/2001	2001-236186	27/FEB/1996	5494829
BST0011	US	US	US	10/JUN/1993	08/0765126	20/MAY/1997	5631171
BST0011	US	US	US	31/MAY/1995	08/455643	20/MAR/1996	08/61996
BST0011	US	US	US	20/MAR/1996	08/61996	09/MAY/2000	6060237
BST0011	US	US	US	17/JAN/1995	08/375151	12/MAR/2002	6355429
BST0020	US	US	US	21/OCT/1999	09/425072	31/AUG/2004	6783838
BST0020	US	US	US	18/OCT/2001	09/982858	03/SEP/2013	5552272
BST0021	US	US	US	10/JUN/1993	08/076548	30/JUL/2013	5541057
BST0022	US	US	US	10/JUN/1993	08/076552	15/JUN/1995	6943446.0
BST0023	DE	DE	DE	02/DEC/1994	943088983.9	02/DEC/2014	02/DEC/2014

BST0023	EP	02/DEC/1994	94308983.9	16/JUN/2005	0659437
BST0023	ES	02/DEC/1994	94308983.9	15/JUN/2005	0659437
BST0023	FR	02/DEC/1994	94308983.9	16/JUN/2005	0659437
BST0023	GB	02/DEC/1994	94308983.9	16/JUN/2005	0659437
BST0023	HK	02/DEC/1994	98100898.6	23/SEP/2005	1001685
BST0023	IT	02/DEC/1994	94308983.9	15/JUN/2005	0659437
BST0023	US	03/DEC/1993	08/162401	27/FEB/1996	5494801
BST0024	AU	21/JUN/1999	98603499	26/SEP/2002	747986
BST0024	CA	21/JUN/1999	2334584	03/MAY/2005	2334584
BST0024	CN	21/JUN/1999	98806819.5	07/APR/2004	98806819.5
BST0024	DE	21/JUN/1999	98933568.0	12/NOV/2003	1089800
BST0024	EP	21/JUN/1999	98933568.0	12/NOV/2003	1089800
BST0024	ES	21/JUN/1999	98933568.0	12/NOV/2003	1089800
BST0024	FR	21/JUN/1999	98933568.0	12/NOV/2003	1089800
BST0024	GB	21/JUN/1999	98933568.0	12/NOV/2003	1089800
BST0024	HK	21/JUN/1999	01107099.4	30/SEP/2004	1036236
BST0024	IN	21/JUN/1999	IN/PC/T2000/000662	12/NOV/2003	1089800
BST0024	IT	21/JUN/1999	98933568.0	12/NOV/2003	1089800
BST0024	JP	21/JUN/1999	2004-297557	16/FEB/2007	3916868
BST0024	JP	21/JUN/1999	2000-556349	28/JAN/2006	121411A
BST0024	MY	22/JUN/1999	P19802560	30/JUN/2003	78192
BST0024	SG	21/JUN/1999	200007494.8	20/FEB/2001	N-121230
BST0024	TW	24/JUN/1999	881105681	18/JUL/2000	8090572
BST0024	US	28/JUN/1998	09/105309	27/MAR/2001	6207445
BST0024	US	17/JUL/2000	09/1617394	20/AUG/2004	772685
BST0025	AU	06/MAR/2000	3/27/100		
BST0025	CA	06/MAR/2000	2366307		
BST0025	CN	06/MAR/2000	00805077.6	02/JUN/2006	199289
BST0025	EP	06/MAR/2000	00816114.2	19/JAN/2007	0674525
BST0025	HK	06/MAR/2000	02104871.0	28/NOV/2003	83390
BST0025	IN	06/MAR/2000	IN/PC/T2001/000958	11/DEC/2001	N-146426
BST0025	JP	06/MAR/2000	2000-605207	11/SEP/2001	6287783
BST0025	KR	06/MAR/2000	10-2801-7011848	03/AUG/2004	6770447
BST0025	SG	06/MAR/2000	20010541.47	12/JUL/2001	09/805146
BST0025	TW	06/APR/2000	89104986	23/JAN/2007	0675698
BST0025	US	18/MAR/1999	09/22/2641	11/JAN/2003	N-169901
BST0025	US	12/JUL/2001	09/805146	02/DEC/2003	6656428
BST0026	CN	03/AUG/2000	03812022.4	09/AUG/2001	732463
BST0026	EP	03/AUG/2000	00952567.6	20/OCT/1997	97911850.2
BST0026	JP	03/AUG/2000	2001-515978	20/OCT/1997	97911850.2
BST0026	JP	03/AUG/2000	2005-379016	20/OCT/1997	97911850.2
BST0026	KR	03/AUG/2000	10-2092-7001601	20/OCT/1997	97911850.2
BST0026	TW	26/SEP/2000	89115787	20/OCT/1997	97911850.2
BST0026	US	03/AUG/2000	09/632343	20/OCT/1997	97911850.2
BST0027	AU	20/OCT/1997	49129/97	09/AUG/2001	732463
BST0027	EP	20/OCT/1997	97911850.2	20/OCT/1997	97911850.2
BST0027	HK	20/OCT/1997	W-990278	20/OCT/1997	97911850.2
BST0027	ID	20/OCT/1997	W-990278	20/OCT/1997	97911850.2

BST0027	JP	20/OCT/1997	1998-520567	23/APR/2004	3547454
BST0027	JP	20/OCT/1997	2003-312436	12/JAN/2007	3906289
BST0027	TW	20/OCT/1997	86116219	21/JUN/2004	NI-203864
BST0027	US	15/OCT/1997	08950963	26/DEC/2006	7153651
BST0027	US	29/SEP/2000	091675518	23/AUG/2005	6933112
BST0028	AU	17/DEC/1998	21941/00	03/JUN/2004	770194
BST0028	CN	17/DEC/1998	200710135987.8		
BST0028	CN	17/DEC/1998	59815096.7		
BST0028	EP	17/DEC/1998	999685392.5		
BST0028	HK	17/DEC/1998	02100371.7		
BST0028	IN	17/DEC/1998	281/DELNP/2006		
BST0028	JP	17/DEC/1998	2006-3228455		
BST0028	MY	21/DEC/1999	P19305611	28/JAN/2006	MV-121411-A
BST0028	SG	17/DEC/1999	200103852.0	29/AUG/2003	81760
BST0028	TW	17/DEC/1999	88122268	11/DEC/2001	NL-146232
BST0028	US	29/DEC/1998	09/223086		
BST0028	CN	03/AUG/2000	00811055.7	22/MAR/2006	00811055.7
BST0030	CN	03/AUG/2010	200510085540.5		
BST0030	EP	03/AUG/2010	00953853.9		
BST0030	IN	03/AUG/2010	IN/PCT/2010/00161		
BST0030	JP	03/AUG/2010	2004-219493		
BST0030	JP	03/AUG/2010	2001-515220	10/FEB/2005	3645523
BST0030	KR	03/AUG/2010	10-2002-7001557	19/NOV/2002	6483585
BST0030	US	04/AUG/2010	09/633036		
BST0030	CN	14/APR/2004	2004480013032.1		
BST0030	EP	14/APR/2004	04750150.7		
BST0030	HK	14/APR/2004	06102354.0		
BST0032	IN	14/APR/2004	3751/DELNP/2005		
BST0032	JP	14/APR/2004	2006-510051		
BST0032	KR	14/APR/2004	10-2005-7019594		
BST0032	US	16/APR/2003	10/417883		
BST0032	ES	21/SEP/1998	146394	06/JUL/2000	146394
BST0032	JP	22/MAR/1999	11-025681	06/APR/2001	1110973
BST0032	US	22/MAR/1999	29/102413	10/OCT/2000	D431867
ISC0008	US	02/OCT/2003	10/679699		
ISC0008	US	02/OCT/2003	09/165926	08/OCT/2002	6461875
ISC0009	US	02/OCT/1998	09/165926	10/DEC/2002	6492179
ISC0009	US	02/OCT/1998	09/165581	09/MAR/2005	0596925
ISC0009	AT	10/JUL/1992	92915563.8	26/AUG/1999	70300
ISC0009	AU	10/JUL/1992	10006197	09/MAR/2005	0596925
ISC0009	BE	10/JUL/1992	92915563.8	02/MAY/2001	P19206312.8
ISC0009	BR	10/JUL/1992	P19206312.8	10/JAN/2008	2113266
ISC0009	CA	10/JUL/1992	92915563.8	09/MAR/2005	0596925
ISC0009	CH	10/JUL/1992	92915563.8	09/MAR/2005	69233487.4
ISC0009	DE	10/JUL/1992	92915563.8	09/MAR/2005	0596925
ISC0009	DK	10/JUL/1992	92915563.8	09/MAR/2005	0596925
ISC0009	EP	10/JUL/1992	92915563.8	09/MAR/2005	0596925
ISC0009	EP	01/DEC/2003	03027486.4	10/JUL/2012	10/JUL/2012

ISC0005	ES	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISC0005	FR	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISC0005	GB	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISC0005	GR	10/JUL/1992	92915563.8	09/MAR/2005	3053499	10/JUL/2012
ISC0005	IE	24/JUL/1992	199212421	18/FEB/2006	84165	24/JUL/2012
ISC0005	IE	02/AUG/2005	2005/05/15	09/MAR/2005	0596925	24/JUL/2012
ISC0005	IT	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISC0005	JP	10/JUL/1992	503561793	01/JUN/2001	319452	10/JUL/2012
ISC0005	KR	10/JUL/1992	7002251/94	23/OCT/1999	239947	10/JUL/2012
ISC0005	LU	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISC0005	MC	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISC0005	NL	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISC0005	NO	10/JUL/1992	92915563.8	16/DEC/2002	313900	10/JUL/2012
ISC0005	PT	24/JUL/1992	100724	14/APR/1999	100724	14/APR/2014
ISC0005	SE	10/JUL/1992	92915563.8	09/MAR/2005	0596925	10/JUL/2012
ISC0005	US	26/JUL/1991	077736583	13/JUL/1993	5227307	26/JUL/2011
ISC0005	US	12/FEB/1993	08016971	01/MAR/1994	5280519	01/OCT/2019
ISC0006	EP	01/OCT/1998	9395005.6	05/NOV/2002	6475743	02/OCT/2018
ISC0006	US	02/OCT/1998	09/165961	04/JUL/2006	7070937	02/OCT/2018
ISC0006	US	29/MAR/2001	09/IB20416	27/MAY/2004	7697727	02/OCT/2018
ISC0006	US	30/AUG/2002	10/232341	31/JAN/2005	11/049020	02/OCT/2018
ISC0006	US	30/MAY/2002	02734574.3	01/OCT/1998	93951710.5	30/MAY/2022
ISC0006	US	30/MAY/2002	10/477384	01/OCT/1998	64095/39	01/OCT/2019
ISC0007	AU	01/OCT/1998	93951710.5	01/OCT/1998	93951710.5	01/OCT/2019
ISC0010	CA	01/OCT/1998	2344762	01/OCT/1998	93951710.5	01/OCT/2019
ISC0010	EP	01/OCT/1998	93951710.5	01/OCT/1998	93951710.5	01/OCT/2019
ISC0010	JP	01/OCT/1998	2000-574907	15/APR/2003	10/414469	01/OCT/2019
ISC0010	US	01/OCT/1998	64095/39	15/APR/2003	10/413832	01/OCT/2019
ISC0010	US	01/OCT/1998	64095/39	15/APR/2003	10/414386	01/OCT/2019
ISC0010	US	01/OCT/1998	64095/39	15/APR/2003	10/413831	01/OCT/2019
ISC0011	US	13/DEC/2002	10/319263	12/JAN/2005	1/1033765	02/OCT/2018
ISC0011	US	12/JAN/2005	1/1033765	26/NOV/2002	200235259	26/NOV/2022
ISC0012	AU	26/NOV/2002	2468236	26/NOV/2002	2468236	26/NOV/2022
ISC0012	CA	26/NOV/2002	027349919.4	26/NOV/2002	027349919.4	26/NOV/2022
ISC0012	EP	26/NOV/2002	027349919.4	26/NOV/2002	10/304610	26/NOV/2021
ISC0012	JP	26/NOV/2002	027349919.4	01/MAY/2006	1/1415829	30/APR/2022
ISC0012	US	26/NOV/2002	027349919.4	30/APR/2002	200230535	30/APR/2022
ISC0013	CA	30/APR/2002	2446187	27/DEC/2006	60217102.4	30/APR/2022
ISC0013	DE	30/APR/2002	02734148.6	27/DEC/2006	1392150	30/APR/2022
ISC0013	EP	30/APR/2002	02734148.6	27/DEC/2006	1392150	30/APR/2022
ISC0013	FR	30/APR/2002	02734148.6	27/DEC/2006	1392150	30/APR/2022
ISC0013	GB	30/APR/2002	02734148.6	27/DEC/2006	1392150	30/APR/2022
ISC0013	JP	30/APR/2002	2002-556801	04/MAY/2001	09/64956	04/MAY/2021
ISC0013	US	30/APR/2002	02734148.6	04/MAY/2001	09/64956	04/MAY/2021

ISC0014	AU	29/APR/2002	2002308530	Ischemia Technologies, Inc.
ISC0014	CA	29/APR/2002	24465329	Ischemia Technologies, Inc.
ISC0014	EP	29/APR/2002	02768855.6	Ischemia Technologies, Inc.
ISC0014	JP	29/APR/2002	2002-085988	Ischemia Technologies, Inc.
ISC0014	US	01/MAY/2001	09/846411	01/MAY/2021
ISC0015	AU	05/MAY/2004	2004240557	05/MAY/2024
ISC0015	CA	05/MAY/2004	2524530	05/MAY/2024
ISC0015	CN	05/MAY/2004	200480013619.0	05/MAY/2024
ISC0015	EP	05/MAY/2004	04751679.4	05/MAY/2024
ISC0015	HK	05/MAY/2004	08110013.6	05/MAY/2024
ISC0015	IL	05/MAY/2004	1711781	05/MAY/2024
ISC0015	IN	05/MAY/2004	2134/IKOLNP/2005	05/MAY/2024
ISC0015	JP	05/MAY/2004	2006-532875	05/MAY/2024
ISC0015	KR	05/MAY/2004	2006-7020921	05/MAY/2024
ISC0015	NZ	05/MAY/2004	543538	05/MAY/2024
ISC0015	SG	05/MAY/2004	200507054.7	14/MAY/2024
ISC0015	US	19/MAY/2003	10/441155	19/MAY/2023
ISC0015	US	22/DEC/2005	11/317831	23/JAN/2026
ISC0016	EP	23/JAN/2006	06/719254.3	20/APR/2013
SELF D0001	US	10/MAR/1998	29/084813	04/APR/2014
SELF D0001	US	24/SEP/1998	094066	Selfcare
SELF D0001	US			Selfcare

SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

D. REGISTERED TRADEMARKS

[Include Owner, Registration Number and Date]

E. TRADEMARK APPLICATIONS

[Include Owner, Application Number and Date]

F. REGISTERED IP LICENSES AND ANY APPLICATIONS THEREFOR

[Include complete legal description of agreement (name of agreement, parties and date)]

TRADEMARK
REEL: 003575 FRAME: 0646

TRADEMARK
REEL: 003575 FRAME: 0652

Comments - The article and incentive \$82,115 outcome of 6/23/2007

**COUNTERPART TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of June 29, 2007, is delivered pursuant to that certain Second Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedules IA, IB and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedules IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

BIOSITE INCORPORATED

By: 
Name: David Teitel
Title: Treasurer

Approved
As To Form


Legal Department

[SIGNATURE PAGE TO SECOND LIEN COUNTERPART TO IP SECURITY AGREEMENT]

LEGAL_US_E # 75512367

TRADEMARK
REEL: 003575 FRAME: 0654

SUPPLEMENTAL SCHEDULES
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Biosite Incorporated as a Grantor to the Second Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of June 29, 2007 and give effect to, and contain data relating to, the acquisition by a wholly-owned subsidiary of Inverness Medical Innovations, Inc. of the capital stock of Biosite Incorporated only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None.

**SCHEDULE 1B
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

See attached list of patents.

Title	Inventor	Application No. Filing Date	Patent No. Issue Date
Polypeptides Related to Natriuretic Peptides and Methods of their Identification and Use	Buechler, Kenneth F. Fung, Eric Thomas Yip, Tai-Tung	2522709 04/19/2004	
Polypeptides Related to Natriuretic Peptides and Methods of Their Identification and Use	Buechler, Kenneth F. Fung, Eric Thomas Yip, Tai-Tung	10/8227919 04/19/2004	
Human Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	09/453234 12/01/1999	6794132 09/21/2004
Human Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils Buechler, Joe Valkirs, Gunars E.	10/111365 04/01/2002	7135287 11/14/2006
Human Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	11/521060 09/13/2006	
Human Antibodies as Diagnostic Reagents	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	09/456090 12/06/1999	6680209 01/20/2004
Human Antibodies as Diagnostic Reagents	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	10/149737 06/06/2002	7189515 03/13/2007
Human Antibodies as Detection Reagents	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	11/685068 03/12/2007	
Assays and Kits for Detecting Analytes In the Presence of Cross-Reacting Substances	Valkirs, Gunars E.	08/006341 01/19/1993	5914241 06/22/1999
Methods for Concentrating Ligands Using Magnetic Particles	Valkirs, Gunars E.	09/054918 04/03/1998	6348318 02/19/2002
Polyvalent Display Libraries	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	08/832985 04/04/1997	6057098 05/02/2000
Polyvalent Display Libraries	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	09/563055 05/01/2000	6985986 01/17/2006

TRADEMARK

REEL: 003575 FRAME: 0658

Title	Inventor	Application No. Filing Date	Patent No. Issue Date
Polyclonal Libraries	Gray, Jeff Buechler, Joe Valkirs, Gunars E.	08/835159 04/04/1997	6555310 04/29/2003
Diagnostic Tests and Kits for Clostridium Difficile	Valkirs, Gunars E.	08/832935 04/04/1997	5965375 10/12/1999
Diagnostic Tests and Kits for Clostridium Difficile	Valkirs, Gunars E.	09/363960	6503722
Recombinant Library Screening Methods	Dower, William J. Cwirla, Steven E.	07/29/1999 07/517659 05/01/1990	01/07/2003 5427908 06/27/1995
Recombinant Library Screening Methods	Dower, William J. Cwirla, Steven E.	08/376326 01/20/1995	5580717 12/03/1996
RECOMBINANT LIBRARY SCREENING METHODS	Dower, William J. Cwirla, Steven E.	08/450754 05/25/1995	
DIAGNOSTIC ASSAY FOR DETECTION OF CRYPTOSPORIDIUM PARVUM	Gray, Jeff Valkirs, Gunars E. Buechler, Joe	09/158180 09/21/1998	
Diagnostic Assays for Detection of Cryptosporidium Parvum	Gray, Jeff Valkirs, Gunars E. Buechler, Joe	09/877933 06/07/2001	7052858 05/30/2006
Diagnostic Assays for Detection of Giardia Lamblia	Buechler, Joe Govindaraj, Shanthi Gray, Jeff Valkirs, Gunars E.	10/155163 05/23/2002	6908739 06/21/2005
Diagnostic Assays for Detection of Entamoeba Histolytica	Valkirs, Gunars E. Buechler, Joe Gray, Jeff	09/158347 09/21/1998	6207395 03/27/2001
Chimeric Polyclonal Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	09/410903 10/02/1999	6420113 07/16/2002
Chimeric Polyclonal Antibodies	Buechler, Joe	10/193960 07/12/2002	
Use of a Tag to Enrich Polypeptides Libraries	Buechler, Joe Valkirs, Gunars Gray, Jeff	11/015628 12/16/2004	
Assays for Detection of Bacillus Anthracis	Lee, Bruce A. Flores, Becky M. Valkirs, Gunars E.	09/754947 01/04/2001	6828110 12/07/2004

Title	Inventor	Application No.	Patent No.
		Filing Date	Issue Date
Assays for Detection of Bacillus Anthracis	Lee, Bruce A. Flores, Becky M. Valkins, Gunars E.	10/890083 07/12/2004	
Methods for Detecting B. Anthracis Infection	Valkins, Gunars E. Buechler, Kenneth F.	10/339744 01/08/2003	
Methods for Detecting B. Anthracis Infection	Valkins, Gunars E. Buechler, Kenneth F.	10/447300 05/27/2003	
Compositions and Methods for Phage Display of Polypeptides	Gray, Jeff Valkins, Gunars E.	11/198920 08/05/2005	
Latent Protein C Assays and Their Uses for Diagnosis and/or Prognosis in Systemic Inflammatory Response Syndromes	Valkins, Gunars E. Buechler, Joe	11/614836 12/21/2006	
High Sensitivity Secretagogin Assays and Their Uses for Diagnosis and/or Prognosis	Buechler, Joe Nakamura, Kevin	11/654901 01/17/2007	

TITLE	INVENTORS	CNTRY	SERIAL NO./ FILING DATE	REG NO./ REG. DATE
Devices and Methods for Performing Receptor Binding Assays Using Magnetic Particles	John Michael Anderberg David M. Gregory	USA	60/834,073 07/28/2006	
Methods and Compositions For Monitoring And Risk Prediction in Cardiorenal Syndrome	Gunars Valkirs Paul H. McPherson	USA	60/859,137 11/14/2006	
Methods and compositions for monitoring and risk prediction in cardiorenal syndrome	Gunars Valkirs Paul H. McPherson	USA	60/891,342 02/23/2007	
Method and Compositions for Diagnosis and Prognosis of Renal Artery Stenosis	Gunars Valkirs Paul H. McPherson	USA	60/859,136 11/14/2006	

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	11/512743	8/29/2006			USE OF SOLUBLE FLT-1 AND ITS FRAGMENTS IN CARDIOVASCULAR CONDITIONS
United States of America	11/684498	3/9/2007			METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF DISEASES OF THE AORTA
United States of America	11/752135	5/22/2007			USE OF Natriuretic Peptides AS DIAGNOSTIC AND PROGNOSTIC INDICATORS IN VASCULAR DISEASES
United States of America	07/583738	10/10/1990	50391512	2/25/1992	Fibrinogen-specific monoclonal antibody
United States of America	07/364053	6/8/1989	5120834	6/9/1992	Fibrin-specific monoclonal antibody
United States of America	07/835800	2/14/1992	5223410	6/29/1993	Method for production of antibodies using an antigen-free animal
United States of America	07/295568	1/10/1989	5028535	7/2/1991	THRESHOLD LIGAND-RECEPTOR ASSAY
United States of America	08/284035	8/1/1994	5679526	10/21/1997	THRESHOLD LIGAND-RECEPTOR ASSAY
United States of America	08/871900	6/11/1997	5939272	8/17/1999	NON-COMPETITIVE THRESHOLD LIGAND-RECEPTOR ASSAYS
United States of America	08/458276	6/21/1995	5922615	7/13/1999	DEVICE FOR LIGAND RECEPTOR METHODS
United States of America	09/249321	2/11/1999	6297060	10/22/2001	DEVICE FOR LIGAND RECEPTOR METHODS
United States of America	07/463150	1/10/1990	5089391	2/18/1992	THRESHOLD LIGAND-RECEPTOR ASSAY
United States of America	07/583046	9/14/1990	5143852	9/1/1992	ANTIBODIES TO LIGAND ANALOGUES AND THEIR UTILITY IN LIGAND-RECEPTOR ASSAYS
United States of America	07/808515	12/16/1991	5233042	8/3/1993	NOVEL COCAINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE COCAINE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864110			5/9/1995	NOVEL BARBITURATE DERIVATIVES AND PROTEIN AND POLYPEPTIDE BARBITURATE DERIVATIVE CONJUGATES AND LABELS

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	07/864108	4/6/1992	5470997	11/28/1995	AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864106	4/6/1992	5237057	8/17/1993	NOVEL TETRAHYDROCANNABINOL DERIVATIVES AND PROTEIN AND POLYPEPTIDE TETRAHYDROCANNABINOL DERIVATIVE CONJUGATES AND LABELS
United States of America	08/032598	3/17/1993	5302703	4/12/1994	TETRAHYDROCANNABINOL DERIVATIVES AND PROTEIN AND POLYPEPTIDE TETRAHYDROCANNABINOL DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864093	4/6/1992	5302715	4/12/1994	NOVEL BENZODIAZEPINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE BENZODIAZEPINE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864104	4/6/1992	5331109	7/19/1994	PHENCYCLIDINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE PHENCYCLIDINE DERIVATIVE CONJUGATES AND LABELS
United States of America	08/241061	5/11/1994	6777190	8/17/2004	CROSSTALK INHIBITORS AND THEIR USES
United States of America	08/101677	8/3/1993	5525524	6/1/1996	CROSSTALK INHIBITORS AND THEIR USES
United States of America	07/987526	5/21/1992	5458852	10/17/1995	DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF A REAGENT WITHOUT MEMBRANES
United States of America	08/447895	5/23/1995	6019944	2/1/2000	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES

BIOSITE Case Listing

Country	Application Number	Application Date	Patient Number	Grant Date	Title
United States of America	08/447981	5/23/1995	5885527	3/23/1999	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/828041	3/27/1997	6156270	12/5/2000	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/902775	7/30/1997	6271040	8/7/2001	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/810569	3/3/1997	6143576	11/7/2000	NON-POROUS DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF REAGENTS
United States of America	09/613650	7/11/2000			DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	09/805653	3/13/2001	6767510	7/27/2004	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	09/982629	10/18/2001	6905882	6/14/2005	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	10/697351	10/29/2003			DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	10792258	3/2/2004			DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	11/022297	12/22/2004			DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	08/416034		4/3/1995 5770256	1/20/1998	METHADONE DERIVATIVES AND PROTEIN AND POLYPEPTIDE METHADONE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/973997	11/9/1992	6037455	3/14/2000	PROPOXYPHENE DERIVATIVES AND PROTEIN AND POLYPEPTIDE PROPOXYPHENE DERIVATIVE CONJUGATES AND LABELS
United States of America	08/071203	6/1/1993	5480792	1/21/1996	ANTIBODIES TO COMPLEXES OF LIGAND RECEPTORS AND LIGANDS AND THEIR UTILITY IN LIGAND-RECEPTOR ASSAYS
United States of America	08/458901	6/2/1995	5935579	11/16/1999	ANTIBODIES TO COMPLEXES OF LIGAND RECEPTORS AND LIGANDS AND THEIR UTILITY IN LIGAND-RECEPTOR ASSAYS
United States of America	08/101782	8/3/1993	58851776	12/22/1998	CONJUGATES AND ASSAYS FOR SIMULTANEOUS DETECTION OF MULTIPLE LIGANDS
United States of America	08/311098	9/23/1994	5763189	6/9/1998	FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN MICROPARTICLES USING NOVEL COMPOUNDS
United States of America	08/409298	3/23/1995	6251687	6/26/2001	FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN PARTICLES USING NOVEL COMPOUNDS
United States of America	08/389969	2/15/1995	5610283	3/11/1997	OPIATE DERIVATIVES AND PROTEIN AND POLYPEPTIDE OPIATE DERIVATIVE CONJUGATION AND LABELS
United States of America	08/423582	4/18/1995	5795725	8/18/1998	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS

BIOSITE Case Listing

Country	Application Number	Application Date	Patient Number	Grant Date	Title
United States of America	08/633248	4/18/1996	61174686	1/16/2001	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	08/7769077	12/18/1996	6627404	9/30/2003	METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	09/349194	7/7/1999	69339678	9/6/2005	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	09/425318	10/21/1999	6579687	6/17/2003	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	09/637051	10/12/2000	6991907	1/31/2006	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	10/459006	6/10/2003			METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	10/856954	5/21/2004			NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	11/673397	2/9/2007			METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	08/517949	8/22/1995	6803040	10/12/2004	DERIVATIVES OF TRICYCLIC ANTIDEPRESSANTS AND PROTEIN AND POLYPEPTIDE TRICYCLIC ANTIDEPRESSANT DERIVATIVE CONJUGATES AND LABELS

BIOSITE Case Listing

Country	Application Number	Application Date	Patient Number	Grant Date	Title
United States of America	08/704804	8/26/1996	63391265	5/21/2002	DEVICES INCORPORATING FILTERS FOR FILTERING FLUID SAMPLES
United States of America	10/153423	5/21/2002			DEVICES FOR INCORPORATING FILTERS FOR FILTERING FLUID SAMPLES
United States of America	08/620597	3/22/1996	5824799	10/20/1998	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	09/776599	2/1/2001	7033984	8/1/2006	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	08/274534	7/12/1994	62338931	5/29/2001	FLUORESCENCE ENERGY TRANSFER AND PARTICLES
United States of America	09/066255	4/24/1998	6964844	11/15/2005	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	11/448613	6/6/2006			HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	08/7749702	11/15/1996	6113855	9/5/2000	DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	09/612815	7/10/2000	6659807	12/30/2003	DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	10/746282	12/24/2003			DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	08/637309	4/9/1997	6544797	4/8/2003	COMPOSITIONS AND METHODS FOR INHIBITING LIGHT-INDUCED INACTIVATION OF BIOLOGICAL REAGENTS
United States of America	10/338182	1/7/2003			NOVEL COMPOSITIONS AND METHODS FOR INHIBITING LIGHT-INDUCED INACTIVATION OF BIOLOGICAL REAGENTS
United States of America	09/081722		513/1998	6670196	12/30/2003 RAPID EVALUATION OF THE RATIO OF BIOLOGICAL MOLECULES
United States of America	10/697356		10/29/2003	7202042	4/10/2007 RAPID EVALUATION OF THE RATIO OF BIOLOGICAL MOLECULES
United States of America	08/821888		3/21/1997	5947124	9/7/1999 DIAGNOSTIC FOR DETERMINING THE TIME OF A HEART ATTACK
United States of America	08/942370		10/2/1997	6106779	8/22/2000 A LYSIS CHAMBER FOR USE IN AN ASSAY DEVICE
United States of America	09/003066		1/5/1998	6074616	6/13/2000 MEDIA CARRIER FOR AN ASSAY DEVICE

BIOSITE Case Listing

Country	Application Number	Application Date	Patient Number	Grant Date	Title
United States of America	09/545699	4/6/2000	6332894	5/21/2002	MEDIA CARRIER FOR AN ASSAY DEVICE
United States of America	07/299277	1/23/1989	5202234	4/13/1993	MYOCARDIAL INFARCTION ASSAY
United States of America	07/882299	5/13/1992	5329592	7/5/1994	FLUORESCENT MICROPARTICLES WITH CONTROLLABLE ENHANCED STOKE SHIFT
United States of America	09/358130	7/20/1999	6302919	10/16/2001	REVERSE-FLOW CENTRIFUGAL FILTRATION METHOD
United States of America	11/204764	8/15/2005			USE OF A GLUTATHIONE PEROXIDASE 1 AS A MARKER IN CARDIOVASCULAR CONDITIONS
United States of America	09/003090	1/5/1998	6830731	12/14/2004	IMMUNOASSAY FLUOROMETER
United States of America	10/267232	10/8/2002			IMMUNOASSAY FLUOROMETER
United States of America	10/841274	5/7/2004			IMMUNOASSAY FLUOROMETER
United States of America	09/003065	1/5/1998	6194222	2/27/2001	METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS
United States of America	09/712615	1/1/13/2000			METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS
United States of America	11/676032	2/16/2007			METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS
United States of America	08/893750	12/19/1997	6156521	12/5/2000	METHODS FOR THE RECOVERY AND MEASUREMENT OF TROPOININ COMPLEXES
United States of America	09/835298	4/13/2001			USE OF B-TYPE Natriuretic Peptide AS A PROGNOSTIC INDICATOR IN ACUTE CORONARY SYNDROMES
United States of America	10/3889720	3/13/2003			USE OF B-TYPE Natriuretic Peptide AS A PROGNOSTIC INDICATOR IN ACUTE CORONARY SYNDROMES
United States of America	10/225082	8/20/2002			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/371149	2/20/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF

BIOSITE Case Listing

Country	Application Number	Application Date	Patient Number	Grant Date	Title
United States of America	10/673077	9/26/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/714078	1/14/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHODS OF USE THEREOF
United States of America	10/875800	6/23/2004			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/330696	12/27/2002			MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	10/728067	12/3/2003			USE OF THROMBUS PRECURSOR PROTEIN AND MONOCYTE CHEMOATTRACTANT PROTEIN AS DIAGNOSTIC AND PROGNOSTIC INDICATORS IN VASCULAR DISEASES
United States of America	10/952275	9/27/2004			METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF SEPSIS
United States of America	11/022552	12/23/2004			METHODS AND COMPOSITIONS FOR DETERMINING TREATMENT REGIMENS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	10/759216	1/20/2004			BIOMARKERS FOR SEPSIS
United States of America	11/543312	10/3/2006			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	11/690767	3/23/2007			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	11/770608	6/28/2007			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America					ARGININE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE

BIOSITE Case Listing

Country	Application Number	Application Date	Patient Number	Grant Date	Title
United States of America	10/139086	5/4/2002			DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROME AND METHODS OF USE THEREOF
United States of America	11/205571	8/17/2005			DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROME AND METHODS OF USE THEREOF
United States of America	10/331127	12/27/2002			METHOD AND SYSTEM FOR DISEASE DETECTION USING MARKER COMBINATIONS
United States of America	10/410572	4/8/2003			SYSTEM AND METHOD FOR IDENTIFYING A PANEL OF INDICATORS
United States of America	10/603891	6/24/2003			(PROTEOME) MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	11/737621	4/19/2007			(PROTEOME) MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	10/419059	4/17/2003			POLYPEPTIDES RELATED TO NATRIURETIC PEPTIDES AND METHODS OF THEIR IDENTIFICATION AND USE
United States of America	10/645874	8/20/2003			METHODS AND COMPOSITIONS FOR MEASURING BIOLOGICALLY ACTIVE NATRIURETIC PEPTIDES AND FOR IMPROVING THEIR THERAPEUTIC POTENTIAL
United States of America	10/938760	9/9/2004			METHODS AND COMPOSITIONS FOR MEASURING NATRIURETIC PEPTIDES AND USES THEREOF
United States of America	11/560425	11/16/2006			COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND MYOCARDIAL INFARCTION WITH DIPEPTIDYL PEPTIDASE INHIBITORS OR B TYPE NATRIURETIC PEPTIDE ANALOGUES RESISTANT TO PROLYL-SPECIFIC DIPEPTIDYL DEGRADATION
United States of America	11/222494	9/7/2005			METHODS AND COMPOSITIONS FOR MEASURING CANINE BNP AND USES THEREOF

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	10/778919	2/12/2004	6887952	5/3/2005	N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	11/080211	3/14/2005	6967107	11/22/2005	N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	11/18746	7/19/2005			N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	11/450150	6/9/2006			METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF VENOUS THROMBOEMBOLIC DISEASE

**SCHEDULE 1C
TO
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

See attached list of trademarks.

COUNTRY	TRADEMARK	CLASS(ES)	APPL. NO FILING DATE	REG. NO. ISSUE DATE
US	AN UNFAIR ADVANTAGE	1, 42	75609619 12/21/1998	2453707 05/22/2001
US	BIOSITE DISCOVERY AN UNFAIR ADVANTAGE & Design	1, 5, 42	75655110 03/05/1999	2456030 05/29/2001
US	OMNICLONAL	1, 5	75609841 12/21/1998	2476239 08/07/2001

MARK	COUNTRY	SERIAL NO. FILING DATE	REG. NO./ REG. DATE
MULTI MARKER INDEX	USA	78574,678 02/24/2005	

TRADEMARK
REEL: 003575 FRAME: 0674

Biosite (U.S. only)

Docket Number	Country	Mark	Portfolio Status	Owner No	Application Date	Registration Date	Registration Number
071949-4501	United States of America	IN TIME TO DECIDE	Registered	Biosite Inc	78/056518	4/3/2001	7/30/2002 2601205
071949-4601	United States of America	NEW DIMENSIONS IN DIAGNOSIS	Registered	Biosite Inc	78/072981	7/9/2001	8/26/2003 2757467
071949-4701	United States of America	ASCEND MULTIMUNOASSAY	Registered	Biosite Inc	74/489582	2/14/1994	10/3/1995 1923243
071949-4801	United States of America	BIOSITE (Stylized)	Registered	Biosite Inc	74/260208	3/30/1992	9/28/1993 1794618
071949-4802	United States of America	BIOSITE (Stylized)	Registered	Biosite Inc	74/260475	3/30/1992	10/5/1993 1796567
071949-4819	United States of America	BIOSITE and Design	Registered	Biosite Inc	76/634473	3/28/2005	10/10/2006 3152581
071949-5101	United States of America	TRIAGE	Registered	Biosite Inc	74/525008	5/16/1994	2/6/1996 1954150
071949-5202	United States of America	TpP Stylized	Registered	Biosite Inc	75/172105	9/26/1996	1/14/2003 2673476
071949-6401	United States of America	EXPRESS TEST	Registered	Biosite Inc	75/075619	3/20/1996	12/11/1998 2207727
071949-6402	United States of America	EXPRESS TEST and Design	Registered	Biosite Inc	75/099733	5/2/1996	9/21/1999 2279640
071949-8101	United States of America	CARDIO PROFILER	Registered	Biosite Inc	78/178159	10/24/2002	6/7/2005 2960760

RECORDED: 07/06/2007

TRADEMARK
REEL: 003575 FRAME: 0675